Bifidobacterium infantis 35624

Bifidobacterium infantis 35624 is a case study in why strain specificity matters in probiotics. Developed by gastroenterologists and marketed in the United States as Align, this single bacterial strain has been tested in dedicated, placebo-controlled trials specifically for irritable bowel syndrome — a level of indication-specific evidence that few other probiotics can claim. But the critical detail is in the numbers: “35624” is not a batch code or a marketing suffix. It is the strain identifier, and generic B. infantis without this designation has not been shown to replicate the trial results.

The mechanism centers on immune modulation in the gut mucosa. O’Mahony’s 2005 study in Gastroenterology showed that B. infantis 35624 induces an anti-inflammatory cytokine profile — specifically increasing IL-10 — when exposed to human dendritic cells, while pathogenic bacteria trigger the opposite pro-inflammatory cascade. In IBS patients, this translates to reduced mucosal levels of pro-inflammatory markers IL-6, IL-8, and TNF-α. Whether this immune modulation directly drives symptom improvement or works through normalization of gut-brain axis signaling remains an active research question.

Whorwell’s 2006 trial in the American Journal of Gastroenterology remains the pivotal study. In a randomized, double-blind, placebo-controlled trial of women with IBS, those receiving B. infantis 35624 at 1×10^8 CFU daily showed significant improvements in composite IBS scores at 4 weeks, with specific benefits in abdominal pain, bloating, and bowel dysfunction. Brenner’s 2009 follow-up in the same journal confirmed these findings and further clarified that the benefit was strain-specific — other probiotic formulations tested in the same trial did not show equivalent effects.

The honest framing is that the effect size is modest. IBS is a complex, heterogeneous disorder, and no probiotic is a cure. B. infantis 35624 reduces symptom severity in a subset of IBS patients — particularly those with bloating and abdominal discomfort — but does not eliminate symptoms entirely. Response rates are typically in the 40–50% range versus 20–30% for placebo, meaning many users will not experience meaningful benefit. The 4-week trial duration is also important: benefits build gradually, and discontinuing after a few days is unlikely to yield results.

Safety is excellent in immunocompetent adults. Side effects are minimal, though some users report transient bloating or gas during the first 1–2 weeks of use. As with all live bacterial supplements, immunocompromised patients should exercise caution. The strain does not appear to colonize the gut long-term — benefits are maintained only with continued supplementation.

Practical guidance: The evidence-based dose is 1×10^8 CFU (100 million) daily, taken consistently for 4–8 weeks before assessing response. This is a lower dose than many probiotic supplements, which is important because higher doses of the same strain have not been shown to produce better results and may increase side effects. Take with or without food — consistency matters more than timing. If no benefit is observed after 8 weeks, discontinuation is reasonable. In India, standalone B. infantis 35624 products are scarce; most available probiotics contain multi-strain blends where this strain may or may not be present at therapeutic doses.